Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Cunningham

Surgery Napa, CA Medical Doctor

NPI 1891763553 CMS profile 222044

4 Financial Plz, Napa, CA 94558

Open in the dashboard

General payments

$13,150

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Cunningham of Napa, CA is reported in the CMS Open Payments database as having received $13,150 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,385 26
2024 General $889 32
2023 General $1,414 48
2022 General $1,977 48
2021 General $1,550 48
2020 General $1,747 48
2019 General $4,188 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Cunningham
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Elizabeth Cunningham were reported at $1,385. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Elizabeth Cunningham Surgery median Middle half National median
2019 $4,188 $253 $82–$1,521 $163
2020 $1,747 $131 $40–$706 $114
2021 $1,550 $168 $50–$904 $132
2022 $1,977 $224 $76–$1,218 $149
2023 $1,414 $253 $82–$1,255 $160
2024 $889 $279 $90–$1,381 $164
2025 $1,385 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $3,304 92 payments
  2. Smith+Nephew, Inc. $2,905 64 payments
  3. Medline Industries, Inc. $1,411 24 payments
  4. Abbott Laboratories $856 44 payments
  5. Organogenesis Inc. $610 10 payments
  6. Medtronic Vascular, Inc. $520 6 payments
  7. Ra Medical Systems, Inc. $494 14 payments
  8. Osiris Therapeutics Inc. $452 10 payments
  9. Endomagnetics Ltd $447 4 payments
  10. Cardiovascular Systems Inc. $245 5 payments
  11. Other $1,906 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,150 330 payments
Products named General payments · program years 2019–2025
  1. Hyalomatrix Wound Device $1,377 23 payments
  2. GRAFIX PL Other Advanced Wound Management $1,242 28 payments
  3. Stravix $863 13 payments
  4. (4067) Tack Endo Sys BTK $711 15 payments
  5. GRAFIX PL Other Advanced Wound Management $680 14 payments
  6. GRAFIX $628 13 payments
  7. GrafixPL $588 11 payments
  8. ClosureFast $520 6 payments
  9. (9281) Turbo Elite $512 12 payments
  10. DABRA $465 12 payments
  11. Other $7,603 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$47,658

Medicare's payments for the services billed

Medicare patients

67

Average age 75

Services billed

197

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 72%
Arthritis 52%
Osteoporosis 43%
Diabetes 21%
Depression 18%
Chronic kidney disease 16%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $31
$31 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record